Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Non-24-Hour Sleep-Wake Disorder
Interventions
tasimelteon, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 19 more
Conditions
Non-24-Hour Sleep-Wake Disorder
Interventions
tasimelteon, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 20 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

NCT00291187
Conditions
Insomnia
Interventions
20 mg VEC-162, 50 mg VEC-162, 100 mg VEC-162, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
21 Years to 50 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 16 more
Conditions
Hepatic Impairment
Interventions
tasimelteon
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Non-24-Hour Sleep-Wake Disorder
Interventions
tasimelteon
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 19 more
Completed Phase 3 Interventional Results available

VEC-162 Study in Adult Patients With Primary Insomnia

NCT00548340
Conditions
Primary Insomnia
Interventions
VEC-162 20 mg, Placebo, VEC-162 50 mg
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
35
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 32 more